ES2654906T3 - Método para determinar la cantidad total y/o la concentración de un analito en presencia de una molécula ligante, así como kits, composiciones y usos relacionados con el mismo - Google Patents
Método para determinar la cantidad total y/o la concentración de un analito en presencia de una molécula ligante, así como kits, composiciones y usos relacionados con el mismo Download PDFInfo
- Publication number
- ES2654906T3 ES2654906T3 ES14792817.0T ES14792817T ES2654906T3 ES 2654906 T3 ES2654906 T3 ES 2654906T3 ES 14792817 T ES14792817 T ES 14792817T ES 2654906 T3 ES2654906 T3 ES 2654906T3
- Authority
- ES
- Spain
- Prior art keywords
- analyte
- molecule
- binding
- concentration
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012491 analyte Substances 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 238000001514 detection method Methods 0.000 abstract description 6
- 239000012634 fragment Substances 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KEAYESYHFKHZAL-OUBTZVSYSA-N sodium-24 Chemical compound [24Na] KEAYESYHFKHZAL-OUBTZVSYSA-N 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13005218 | 2013-11-05 | ||
| EP13005218 | 2013-11-05 | ||
| EP14002015 | 2014-06-11 | ||
| EP14002015 | 2014-06-11 | ||
| PCT/EP2014/073523 WO2015067547A1 (en) | 2013-11-05 | 2014-11-03 | A method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2654906T3 true ES2654906T3 (es) | 2018-02-15 |
| ES2654906T8 ES2654906T8 (es) | 2018-02-26 |
Family
ID=51845410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14792817.0T Active ES2654906T3 (es) | 2013-11-05 | 2014-11-03 | Método para determinar la cantidad total y/o la concentración de un analito en presencia de una molécula ligante, así como kits, composiciones y usos relacionados con el mismo |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10564151B2 (enExample) |
| EP (1) | EP3066469B1 (enExample) |
| JP (1) | JP6446044B2 (enExample) |
| CN (1) | CN105683755B (enExample) |
| CA (1) | CA2926306C (enExample) |
| ES (1) | ES2654906T3 (enExample) |
| WO (1) | WO2015067547A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108700576B (zh) * | 2017-01-20 | 2021-07-02 | 深圳市新产业生物医学工程股份有限公司 | 制备抗体对的方法、试剂盒及试剂盒的应用和制备抗体对的系统 |
| WO2024158727A2 (en) * | 2023-01-24 | 2024-08-02 | University Of Cincinnati | Depletion-limited analyte sensing with non-equilibrium binding probes |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| DE4214922C2 (de) | 1992-05-06 | 1996-06-13 | Brahms Diagnostica Gmbh | Verfahren zur quantitativen Bestimmung des Anteils der freien Form eines Schilddrüsenhormon-Liganden in einer biologischen Flüssigkeit und Kit zur Durchführung eines solchen Verfahrens |
| US5312730A (en) * | 1992-05-27 | 1994-05-17 | Ciba Corning Diagnostics Corp. | Immune complex transfer with lypophilic bridge |
| AU4482896A (en) * | 1995-01-31 | 1996-08-21 | Novo Nordisk A/S | A method of diagnosing preclinical diabetes |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| CN1867587A (zh) * | 2003-08-14 | 2006-11-22 | 惠氏公司 | 抗Lewis Y抗独特型抗体及其用途 |
| WO2005108989A2 (en) * | 2004-04-16 | 2005-11-17 | Genentech, Inc. | Assay for antibodies |
| EP1861708A2 (en) * | 2005-03-08 | 2007-12-05 | Tanox, Inc. | Methods for determining the bivalency of protein and antibody therapeutics |
| CN101379399A (zh) | 2005-12-22 | 2009-03-04 | 罗姆股份有限公司 | 免疫测定装置和方法 |
| EP1801594A1 (en) * | 2005-12-23 | 2007-06-27 | Koninklijke Philips Electronics N.V. | Sensing device and method for determination of the amount of target molecule in an analyte |
| US20080127359A1 (en) * | 2006-11-06 | 2008-05-29 | Hermann Beck | Method for producing anti-idiotypic antibodies |
| TWI434855B (zh) * | 2006-11-21 | 2014-04-21 | Hoffmann La Roche | 結合物及其在免疫分析中作為參考標準之用途 |
| EP2193145A4 (en) | 2007-08-28 | 2011-05-18 | Abbott Biotech Ltd | COMPOSITIONS AND METHODS COMPRISING BINDING PROTEINS FOR ADALIMUMAB |
| FR2980271B1 (fr) * | 2011-09-16 | 2013-10-11 | Cisbio Bioassays | Procede de determination de la glycosylation d'un anticorps |
| BR112014011535A2 (pt) * | 2011-12-19 | 2017-05-09 | Hoffmann La Roche | método para a determinação in vitro e imunológica de presença da presença e/ou da quantidade de um parceiro de ligação, método in vitro e utilização de um anticorpo |
| CN104105966B (zh) * | 2012-02-01 | 2016-10-26 | 弗·哈夫曼-拉罗切有限公司 | 用于检测多特异性结合物的结合搭档的方法 |
| WO2014009474A1 (en) * | 2012-07-13 | 2014-01-16 | F. Hoffmann-La Roche Ag | Method for the detection of a multispecific binder |
| PE20160190A1 (es) * | 2013-08-01 | 2016-04-28 | Five Prime Therapeutics Inc | Anticuerpos anti-fgfr2iiib afucosilados |
-
2014
- 2014-11-03 CA CA2926306A patent/CA2926306C/en active Active
- 2014-11-03 JP JP2016527237A patent/JP6446044B2/ja active Active
- 2014-11-03 ES ES14792817.0T patent/ES2654906T3/es active Active
- 2014-11-03 EP EP14792817.0A patent/EP3066469B1/en active Active
- 2014-11-03 CN CN201480060361.3A patent/CN105683755B/zh active Active
- 2014-11-03 WO PCT/EP2014/073523 patent/WO2015067547A1/en not_active Ceased
-
2016
- 2016-05-04 US US15/146,226 patent/US10564151B2/en active Active
-
2020
- 2020-01-06 US US16/734,884 patent/US12158466B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12158466B2 (en) | 2024-12-03 |
| CN105683755A (zh) | 2016-06-15 |
| US20160252500A1 (en) | 2016-09-01 |
| US10564151B2 (en) | 2020-02-18 |
| US20200141930A1 (en) | 2020-05-07 |
| EP3066469B1 (en) | 2017-10-11 |
| EP3066469A1 (en) | 2016-09-14 |
| JP2016535266A (ja) | 2016-11-10 |
| HK1225799A1 (zh) | 2017-09-15 |
| CN105683755B (zh) | 2019-08-13 |
| CA2926306C (en) | 2022-12-06 |
| JP6446044B2 (ja) | 2018-12-26 |
| CA2926306A1 (en) | 2015-05-14 |
| ES2654906T8 (es) | 2018-02-26 |
| WO2015067547A1 (en) | 2015-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2377579T3 (es) | Anticuerpos de alta afinidad contra el receptor de IL-6 humano | |
| ES2910305T3 (es) | Anticuerpos anti-NGF y su uso | |
| ES2595981T3 (es) | Anticuerpo antiidiotipo contra un anticuerpo contra el péptido beta amiloide | |
| US20150111250A1 (en) | Methods and compositions for modulating tumor cell activity | |
| RU2018124602A (ru) | Новые анти-pd-l1 антитела | |
| US20240247037A1 (en) | Glypican epitopes and uses thereof | |
| JP6586648B2 (ja) | 抗プログルカゴン抗体 | |
| ES2654906T3 (es) | Método para determinar la cantidad total y/o la concentración de un analito en presencia de una molécula ligante, así como kits, composiciones y usos relacionados con el mismo | |
| PT2248826E (pt) | Anticorpo dirigido contra pcrv | |
| JP2013136530A (ja) | Ｉｌ−２８ｂの分析方法 | |
| JP2008542366A (ja) | Ｆｚｄ８モジュレーターを同定する方法および変形性関節症を処置するためのそのようなモジュレーターの使用 | |
| ES2778100T3 (es) | Anticuerpos monoclonales anti-gpc-1 y usos de los mismos | |
| CN110724193A (zh) | 人单克隆抗il-32抗体、多核苷酸、载体、宿主细胞、制备方法、组合物及应用 | |
| US20240182556A1 (en) | Stem cell factor antibodies and methods of use thereof | |
| JP5663137B2 (ja) | ミッドカインのｃ−ドメインを認識する抗体 | |
| JP7084057B2 (ja) | 新規抗ｐａｄ２抗体 | |
| JP2023553205A (ja) | Ｓｔｒｅｐ－ＴａｇＩＩタグに特異的に結合する抗体およびその使用 | |
| JP2017109965A (ja) | 抗膵ポリペプチドモノクローナル抗体 | |
| JP6861349B2 (ja) | Ｃｄ８１ ｌｅｌ特異的モノクローナル抗体 | |
| CN112794913B (zh) | 白血病检测试剂盒 | |
| CN110579610A (zh) | 用于检测t细胞活化的v域免疫抑制因子的试剂盒 | |
| JP6462632B2 (ja) | 変異型α−アクチニン−４に対する抗体 | |
| CN102532317B (zh) | Pes1的单克隆抗体及其应用 | |
| EP4602068A1 (en) | Anti-scd146 antibodies and uses thereof | |
| CN118221814A (zh) | 一种抗april抗体及其应用 |